Antibiotic resistance necessitates ongoing development against mutated microbes. This article addresses this challenge by focusing on garenoxacin, a des-fluoro-(6)-quinolone effective against diverse bacteria. Its broad spectrum and superior activity suggest wide usability.1 Studies indicate its benefits for respiratory tract infections compared to other drugs. This article presents garenoxacin's development history to understand quinolone evolution and future potential. It overviews structure, properties, synthesis, and SAR. Modifications led to improved third-generation quinolones. Microbiological and pharmacological studies, comparisons, and interaction compatibility are discussed. An analytical overview for quality management of garenoxacin synthesis and industrial production is also presented.
No takes yet. Share an insight, caveat, or question.
Vyas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: